Trial Profile
A Prospective, Observational, Multicenter Cohort Study to Assess Efficacy and Safety of Vedolizumab in Crohn's Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2020
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms Getaid
- 22 Dec 2019 Results, an analysis of the data from GEMINI-2 study,GETAID and VICTORY dataset assessing the role of clinical decision support tool (CDST) in predicting efficacy of vedolizumab in Crohn's disease, published in the Alimentary Pharmacology and Therapeutics
- 16 Mar 2016 New trial record